PACIRA BIOSCIENCES, INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
PACIRA BIOSCIENCES, INC. (PCRX) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $332.43 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2019-02-28
- PACIRA BIOSCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-12-31 was $94.71M, a 20.15% increase year-over-year.
- PACIRA BIOSCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-09-30 was $82.71M, a 23.54% increase year-over-year.
- PACIRA BIOSCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $80.72M, a 15.08% increase year-over-year.
- PACIRA BIOSCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $74.29M, a 8.57% increase year-over-year.
- PACIRA BIOSCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2018 was $332.43M, a 16.91% increase from fiscal 2017.
- PACIRA BIOSCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $284.34M, a 5.28% increase from fiscal 2016.
- PACIRA BIOSCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $270.07M, a 10.47% increase from fiscal 2015.
- PACIRA BIOSCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $244.49M, a 26.33% increase from fiscal 2014.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-12-31 | $94.71M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $177.42M derived: sum of 2 quarters · filed 2019-02-28 | $258.14M derived: sum of 3 quarters · filed 2019-02-28 | $332.43M 10-K · filed 2019-02-28 |
| 2018-09-30 | $82.71M 10-Q · filed 2018-11-01 | $163.43M derived: sum of 2 quarters · filed 2018-11-01 | $237.71M 10-Q · filed 2018-11-01 | $316.54M derived: sum of 4 quarters · filed 2019-02-28 |
| 2018-06-30 | $80.72M 10-Q · filed 2018-08-02 | $155.00M 10-Q · filed 2018-08-02 | $233.83M derived: sum of 3 quarters · filed 2019-02-28 | $300.78M derived: sum of 4 quarters · filed 2019-02-28 |
| 2018-03-31 | $74.29M 10-Q · filed 2018-05-03 | $153.11M derived: sum of 2 quarters · filed 2019-02-28 | $220.06M derived: sum of 3 quarters · filed 2019-02-28 | $290.20M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-12-31 | $78.83M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $145.78M derived: sum of 2 quarters · filed 2019-02-28 | $215.92M derived: sum of 3 quarters · filed 2019-02-28 | $284.34M 10-K · filed 2019-02-28 |
| 2017-09-30 | $66.95M 10-Q · filed 2018-11-01 | $137.09M derived: sum of 2 quarters · filed 2018-11-01 | $205.51M 10-Q · filed 2018-11-01 | $277.28M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $70.14M 10-Q · filed 2018-08-02 | $138.56M 10-Q · filed 2018-08-02 | $210.33M derived: sum of 3 quarters · filed 2019-02-28 | $276.45M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $68.42M 10-Q · filed 2018-05-03 | $140.19M derived: sum of 2 quarters · filed 2019-02-28 | $206.31M derived: sum of 3 quarters · filed 2019-02-28 | $274.00M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $71.76M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $137.88M derived: sum of 2 quarters · filed 2019-02-28 | $205.57M derived: sum of 3 quarters · filed 2019-02-28 | $270.07M 10-K · filed 2019-02-28 |
| 2016-09-30 | $66.12M 10-Q · filed 2017-11-08 | $133.81M derived: sum of 2 quarters · filed 2017-11-08 | $198.31M 10-Q · filed 2017-11-08 | $266.50M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $67.69M 10-Q · filed 2017-08-02 | $132.19M 10-Q · filed 2017-08-02 | $200.38M derived: sum of 3 quarters · filed 2018-02-28 | $261.53M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | $64.50M 10-Q · filed 2017-05-04 | $132.69M derived: sum of 2 quarters · filed 2018-02-28 | $193.84M derived: sum of 3 quarters · filed 2018-02-28 | $251.90M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | $68.19M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $129.34M derived: sum of 2 quarters · filed 2018-02-28 | $187.40M derived: sum of 3 quarters · filed 2018-02-28 | $244.49M 10-K · filed 2018-02-28 |
| 2015-09-30 | $61.15M 10-Q · filed 2016-11-02 | $119.21M derived: sum of 2 quarters · filed 2016-11-02 | $176.30M 10-Q · filed 2016-11-02 | $369.82M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $58.06M 10-Q · filed 2016-08-04 | $115.15M 10-Q · filed 2016-08-04 | $308.67M derived: sum of 3 quarters · filed 2017-03-01 | $359.59M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $57.09M 10-Q · filed 2016-05-02 | $250.61M derived: sum of 2 quarters · filed 2017-03-01 | $301.53M derived: sum of 3 quarters · filed 2017-03-01 | $347.57M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $193.53M 10-K · filed 2017-03-01 | $244.45M derived: sum of 2 quarters · filed 2017-03-01 | $290.48M derived: sum of 3 quarters · filed 2017-03-01 | $193.53M 10-K · filed 2016-02-25 |
| 2014-09-30 | $50.92M 10-Q · filed 2015-10-27 | $96.95M derived: sum of 2 quarters · filed 2015-10-27 | $132.70M 10-Q · filed 2015-10-27 | $165.13M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $46.03M 10-Q · filed 2015-07-30 | $81.78M 10-Q · filed 2015-07-30 | $114.21M derived: sum of 3 quarters · filed 2016-02-25 | $136.62M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $35.74M 10-Q · filed 2015-04-30 | $68.18M derived: sum of 2 quarters · filed 2016-02-25 | $90.59M derived: sum of 3 quarters · filed 2016-02-25 | $106.86M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $32.44M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $54.84M derived: sum of 2 quarters · filed 2016-02-25 | $71.12M derived: sum of 3 quarters · filed 2016-02-25 | $81.96M 10-K · filed 2016-02-25 |
| 2013-09-30 | $22.41M 10-Q · filed 2014-10-30 | $38.69M derived: sum of 2 quarters · filed 2014-10-30 | $49.52M 10-Q · filed 2014-10-30 | $57.73M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $16.28M 10-Q · filed 2014-07-31 | $27.11M 10-Q · filed 2014-07-31 | $35.33M derived: sum of 3 quarters · filed 2015-02-24 | $39.88M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $10.84M 10-Q · filed 2014-05-01 | $19.05M derived: sum of 2 quarters · filed 2015-02-24 | $23.60M derived: sum of 3 quarters · filed 2015-02-24 | $28.58M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | $8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $12.76M derived: sum of 2 quarters · filed 2015-02-24 | $17.74M derived: sum of 3 quarters · filed 2015-02-24 | $18.19M 10-K · filed 2015-02-24 |
| 2012-09-30 | $4.55M 10-Q · filed 2013-10-31 | $9.53M derived: sum of 2 quarters · filed 2013-10-31 | $9.98M 10-Q · filed 2013-10-31 | $12.00M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | $4.98M 10-Q · filed 2013-08-06 | $5.43M 10-Q · filed 2013-08-06 | $7.45M derived: sum of 3 quarters · filed 2014-02-25 | $9.14M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $446.00K 10-Q · filed 2013-05-08 | $2.47M derived: sum of 2 quarters · filed 2014-02-25 | $4.16M derived: sum of 3 quarters · filed 2014-02-25 | $5.62M derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $3.71M derived: sum of 2 quarters · filed 2014-02-25 | $5.18M derived: sum of 3 quarters · filed 2014-02-25 | $6.89M 10-K · filed 2014-02-25 |
| 2011-09-30 | $1.68M 10-Q · filed 2011-10-31 | $3.15M derived: sum of 2 quarters · filed 2011-10-31 | $4.87M 10-Q · filed 2011-10-31 | |
| 2011-06-30 | $1.47M 10-Q · filed 2011-08-11 | $3.19M 10-Q · filed 2011-08-11 | ||
| 2010-12-31 | $513.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-07 | $3.26M derived: sum of 2 quarters · filed 2013-03-07 | $4.72M derived: sum of 3 quarters · filed 2013-03-07 | $7.64M 10-K · filed 2013-03-07 |
| 2010-09-30 | $2.74M 10-Q · filed 2011-10-31 | $4.20M derived: sum of 2 quarters · filed 2011-10-31 | $7.13M 10-Q · filed 2011-10-31 | |
| 2010-06-30 | $1.46M 10-Q · filed 2011-08-11 | $4.38M 10-Q · filed 2011-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |